In This Week’s Briefing: NYU Launches Psychedelic Training Program, Major Paper Opposes Oregon Legalization,DC Democrats
Similar Posts
MindCure CEO Kelsey Ramsden – The Psychedelic Space Is Unlike Any Other Drug Development Sector
In this interview with Kelsey Ramsden, CEO on MindCure Health…
Medical Applications of Ketamine & Common Misconceptions with Christi Myers, Flow Integrative
In this episode, Christi provides insight into how ketamine impacts people’s physical and mental health. She goes into the comparison of ketamine’s effects compared to other psychedelics and how Flow Integrative’s patient care is unique.
Interview With Lauren Taus
In this episode of the Psychedelic Spotlight podcast we speak with Lauren Taus who is the Founder of INBodied Life, who’s focus is on integrating modern science and ancient wisdom to support transformation.
Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)
What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.
MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Spotlight on Cannara Biotech with Nicholas Sosiak
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company’s future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Interview with Bright Minds Biosciences’ CEO Ian McDonald
In today’s episode of the Psychedelic Spotlight podcast, the Psychedelic…